Furthermore, our analysis identified that younger patients (<60 years), those with negative PR expression, higher Ki67 expression levels, and absence of lymph node metastasis were more likely to respond to pyrotinib treatment. Here, MKI67 is linked to metastatic malignant neoplasm in the lymph nodes.